| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Factor XI and its active form Factor XIa |
| Clinical data | |
| Other names | MAA868 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation, [1] under developement by Anthos Therapeutics.
It is anti-factor XI antibody. [1] [2]
A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
César Milstein, CH, FRS was an Argentine biochemist in the field of antibody research. Milstein shared the Nobel Prize in Physiology or Medicine in 1984 with Niels Kaj Jerne and Georges J. F. Köhler for developing the hybridoma technique for the production of monoclonal antibodies.
The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.
Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.
Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.
Afelimomab is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.
Faralimomab is a mouse monoclonal antibody and an immunomodulator.
Cedelizumab is a monoclonal antibody acting on the immune system. Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases.
Maslimomab is a mouse monoclonal antibody and an immunosuppressive drug. It is an anti-human T-cell receptor alpha/beta chain.
Edobacomab, codenamed E5, is a mouse monoclonal antibody that was investigated as a possible treatment for sepsis caused by Gram-negative bacterial infections.
Technetium (99mTc) nofetumomab merpentan is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer, gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma. The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (99mTc).
Morolimumab is a human monoclonal antibody against the human Rhesus factor.
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
Fulranumab is a monoclonal antibody against nerve growth factor. It was designed for the treatment of pain.
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.
Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS‑CoV‑2.
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.
Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
